These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9696488)

  • 1. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method.
    Duchatelle V; Marcellin P; Giostra E; Bregeaud L; Pouteau M; Boyer N; Auperin A; Guerret S; Erlinger S; Henin D; Degott C
    J Hepatol; 1998 Jul; 29(1):20-8. PubMed ID: 9696488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C.
    Caballero T; Pérez-Milena A; Masseroli M; O'Valle F; Salmerón FJ; Del Moral RM; Sánchez-Salgado G
    J Hepatol; 2001 May; 34(5):740-7. PubMed ID: 11434621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection.
    Muir AJ; Sylvestre PB; Rockey DC
    J Viral Hepat; 2006 May; 13(5):322-8. PubMed ID: 16637863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.
    Everson GT; Jensen DM; Craig JR; van Leeuwen DJ; Bain VG; Ehrinpreis MN; Albert D; Joh T; Witt K
    Hepatology; 1999 Jul; 30(1):271-6. PubMed ID: 10385666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
    Lamers MH; Broekman M; Drenth JP; Gluud C
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD011132. PubMed ID: 24937404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
    Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
    J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis].
    Rao HY; Li J; Zhang LF; Chen HY; Zhu LM; Wei L; Sun Y; Wang H
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):96-100. PubMed ID: 18353212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.
    Shiratori Y; Imazeki F; Moriyama M; Yano M; Arakawa Y; Yokosuka O; Kuroki T; Nishiguchi S; Sata M; Yamada G; Fujiyama S; Yoshida H; Omata M
    Ann Intern Med; 2000 Apr; 132(7):517-24. PubMed ID: 10744587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis.
    D'Ambrosio R; Aghemo A; Rumi MG; Ronchi G; Donato MF; Paradis V; Colombo M; Bedossa P
    Hepatology; 2012 Aug; 56(2):532-43. PubMed ID: 22271347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
    Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
    Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminoadamantanes for chronic hepatitis C.
    Lamers MH; Broekman M; Drenth JP; Gluud C
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD010125. PubMed ID: 24793264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A histopathological study of the effects of 6-month versus 12-month interferon alpha-2b therapy in chronic hepatitis C.
    Ziol M; Nhieu JT; Roudot-Thoraval F; Métreau JM; Deugnier Y; Dhumeaux D; Zafrani ES
    J Hepatol; 1996 Dec; 25(6):833-41. PubMed ID: 9007710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
    Petrenkiene V; Gudinaviciene I; Jonaitis L; Kupcinskas L
    Medicina (Kaunas); 2004; 40(6):538-46. PubMed ID: 15208476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Level of serum tumor necrosis factor-alpha and the degree of liver fibrosis in children with chronic viral hepatitis B, C and B+C, treated with interferon-alpha].
    Filimonov PN; Sukhenko TG; Gavrilova NI
    Zh Mikrobiol Epidemiol Immunobiol; 2002; (2):69-72. PubMed ID: 12043158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment laparoscopic appearance of the liver can predict response to combination therapy with interferon alpha 2B and ribavirin in chronic hepatitis C.
    Bajaj JS; Molina E; Regev A; Schiff ER; Jeffers LJ
    Gastrointest Endosc; 2003 Sep; 58(3):380-3. PubMed ID: 14528212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.
    Hauser G; Awad T; Brok J; Thorlund K; Štimac D; Mabrouk M; Gluud C; Gluud LL
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005441. PubMed ID: 24585509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response.
    Rao HY; Wei L; Li J; Zhang LF; Chen HY; Zhu LM; Liu F; Sun Y; Wang H
    Hepatogastroenterology; 2009; 56(90):328-34. PubMed ID: 19579592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients.
    el-Zayadi A; Selim O; Haddad S; Simmonds P; Hamdy H; Badran HM; Shawky S
    Ital J Gastroenterol Hepatol; 1999; 31(6):472-5. PubMed ID: 10575565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone.
    Koshy A; Madda JP; Marcellin P; Martinot M
    J Clin Gastroenterol; 2002 Jul; 35(1):82-5. PubMed ID: 12080232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.
    Poynard T; McHutchison J; Davis GL; Esteban-Mur R; Goodman Z; Bedossa P; Albrecht J
    Hepatology; 2000 Nov; 32(5):1131-7. PubMed ID: 11050066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.